Oral PrimeC for ALS significantly reduced toxic TDP-43 protein levels in a Phase 2b trial. PrimeC also slowed functional decline and extended survival by about 15 months. The treatment was well ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results